Home Cart Sign in  
Chemical Structure| 90-18-6 Chemical Structure| 90-18-6

Structure of Quercetagetin
CAS No.: 90-18-6

Chemical Structure| 90-18-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Quercetagetin (6-Hydroxyquercetin) is a flavonoid that acts as a moderately potent and selective, cell-permeable pim-1 kinase inhibitor with an IC50 of 0.34 μM. It has anti-inflammatory and antitumor activities.

Synonyms: 6-Hydroxyquercetin; NSC 115916

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Quercetagetin

CAS No. :90-18-6
Formula : C15H10O8
M.W : 318.24
SMILES Code : O=C1C2=C(OC(C3=CC=C(C(O)=C3)O)=C1O)C=C(O)C(O)=C2O
Synonyms :
6-Hydroxyquercetin; NSC 115916
MDL No. :MFCD00017428

Safety of Quercetagetin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of Quercetagetin

epigenetics
JAK-STAT

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
OCI-Ly19 cells 40 μM Evaluate the effect of Quercetagetin on NHL cell proliferation, showing significant toxicity on OCI-Ly19 cells PMC4672512
SUDHL6 cells 40 μM Evaluate the effect of Quercetagetin on NHL cell proliferation, showing anti-proliferative effects on SUDHL6 cells PMC4672512
OCI-Ly10 cells 40 μM Evaluate the effect of Quercetagetin on NHL cell proliferation, showing anti-proliferative effects on OCI-Ly10 cells PMC4672512
OCI-Ly3 cells 40 μM Evaluate the effect of Quercetagetin on NHL cell proliferation, showing anti-proliferative effects on OCI-Ly3 cells PMC4672512
Ramos cells 40 μM Evaluate the effect of Quercetagetin on NHL cell proliferation, showing anti-proliferative effects on Ramos cells PMC4672512
Raji cells 40 μM Evaluate the effect of Quercetagetin on NHL cell proliferation, showing anti-proliferative effects on Raji cells PMC4672512
Huh7.5 cells 40.2±17.7 μM 72 h Evaluate the inhibitory effect of Quercetagetin on HCV genotype 2a infectious strain replication, showing dose-dependent inhibition PMC4132742
Huh7.5 cells 0–100 μM 3 days Western blot analysis showed Quercetagetin dose-dependently inhibited NS5B protein expression PMC4132742
NIH3T3 cells 5 μM, 10 μM, 20 μM Inhibited H-Ras-induced cell transformation PMC3540140
JB6 P+ cells 5 μM, 10 μM, 20 μM Inhibited UVB-induced AP-1 and NF-κB transactivation PMC3540140
Huh7.5 cells 5.4 ±3.3 μM 3 days Evaluate the inhibitory effect of Quercetagetin on HCV genotype 1b subgenomic replicon replication, showing dose-dependent inhibition PMC4132742
H9c2 cardiomyoblasts 10 μM 1 h To investigate the inhibitory effects of Quercetagetin on LPS-induced MAPK phosphorylation and COX-2 expression in H9c2 cells. Results showed that Quercetagetin significantly inhibited LPS-induced phosphorylation of ERK1/2, p38, and JNK, and reduced COX-2 expression. PMC5583969
bone marrow-derived monocytes (BMMs) 2 µM 48 h To evaluate the inhibitory effect of Quercetagetin on LPS-induced osteoclast differentiation. Results showed that 2 µM Quercetagetin significantly inhibited LPS-driven osteoclast differentiation and function. PMC11889843
Caco-2/TC7 cells 1–50 μM 10 min To evaluate the inhibitory ability of Quercetagetin on human α-glucosidases (sucrase, maltase, and isomaltase). Results showed that quercetagetin was the strongest inhibitor of α-glucosidases among the tested flavonols, with inhibition constants approaching those of acarbose. PMC8392382

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
SKH-1 hairless mice Two-stage skin carcinogenesis model Topical application 4 or 20 nmol Significantly inhibited UVB-induced skin cancer development, reduced tumor incidence and volume PMC3540140
DBA/1 male mice Collagen antibody-induced arthritis (CAIA) model Intraperitoneal (IP) injection 40 mg/kg Once daily until day 13 To validate the therapeutic effect of Quercetagetin in the CAIA model. Results showed that 40 mg/kg Quercetagetin significantly alleviated joint destruction and inflammation. PMC11889843
Rabbits ZEN-induced liver injury model Oral 100 mg/kg 28 days To assess the alleviative effect of quercetagetin (QG) on zearalenone (ZEN)-induced liver injury in rabbits. Results showed that QG alleviated the ZEN-induced oxidative damage and liver injury caused by inflammatory reaction through the Keap1-Nrf2-ARE signal pathway. PMC10579610

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.14mL

0.63mL

0.31mL

15.71mL

3.14mL

1.57mL

31.42mL

6.28mL

3.14mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories